ATC Group: H05BX05 Calcifediol

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of H05BX05 in the ATC hierarchy

Level Code Title
1 H Systemic hormonal preparations, excl. Sex hormones and insulins
2 H05 Calcium homeostasis
3 H05B Anti-parathyroid agents
4 H05BX Other anti-parathyroid agents
5 H05BX05

Active ingredients in H05BX05

Active Ingredient Description
Calcidiol

Vitamin D3 must undergo a two-step metabolic process to be active; the first step occurs in the microsomal fraction of the liver where Vitamin D is hydroxylated at position 25 (25-hydroxycholecalciferol or calcifediol); the second step takes place in the kidney where 1,25-dihydroxycholecalciferol or calcitriol is formed due to the activity of enzyme 25-hydroxycholecalciferol 1-hydroxylase. Vitamin D increases absorption of calcium and phosphorus in the intestine and improves normal bone formation and mineralization.

Related product monographs

Title Information Source Document Type  
RAYALDEE Extended-release capsule FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Ireland (IE)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.